

**Remarks**

Claims 1, 4-18 and 20-23 were pending in the present application. Applicant acknowledges with appreciation that the subject matter of claim 23 has been deemed allowable. In order to expedite prosecution of the present application and without conceding to the validity of the Examiner's rejection, Applicant has canceled claims 1, 4-18 and 20-22 without prejudice, and reserves his right to pursue the subject matter of the canceled claims in one or more related applications.


New claims 24-38, all which depend from claim 23, have been added. Upon entry of the present amendment, claims 23-38 will be pending in the present application.

In view of the Examiner's indication that the subject matter of claim 23 is allowable, it is respectfully submitted that claims 24-38, which depend from claim 23, should likewise be deemed allowable.

Accordingly, Applicant respectfully requests that the foregoing amendments and remarks be entered and made of record in the present application. In addition, applicant respectfully requests consideration of the pending claims and early allowance of the application. No additional fee is believed due. However, if any fee is due, the Examiner is authorized to charge the fee to Applicants' Deposit Account No. 16-1445.

Respectfully submitted,

Date: August 31, 2005

  
John C. Martin  
Reg. No. 42,843

Pfizer Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-6872